In third deal of the week, Boehringer partners with Kyowa on fibro-inflammation
License out/inImmunotherapyOligonucleotidesiRNA
Boehringer Ingelheim continued its new year dealmaking spree on Friday, signing a licensing agreement with Kyowa Kirin. The German firm gained exclusive, worldwide rights to a potentially first-in-class treatment for fibro-inflammatory diseases.
The deal is worth up to €410 million, which includes an upfront payment and development, regulatory, and commercial milestones. Kyowa is also eligible for royalties.
The licensing deal comes days after Boehringer inked another inflammation-focused partnership. On Wednesday, the company agreed to pay Suzhou Ribo Life Science up to $2 billion to develop small interfering RNA (siRNA) therapies to treat metabolic dysfunction-associated steatohepatitis (MASH).
Boehringer’s collaboration roster this week also included 3T Biosciences. On Thursday, the pair agreed to a second discovery deal for T-cell based cancer immunotherapies.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.